• Molecular NameDihydroergotamine
  • Synonym9,10-dihydro-ergotamine; Dihidroergotamina [INN-Spanish]; Dihydroergotamine mesylate; Dihydroergotamine methanesulfonate; Dihydroergotamine monomethanesulfonate; Dihydroergotaminum [INN-Latin]
  • Weight583.689
  • Drugbank_IDDB00320
  • ACS_NO5111-12-6
  • Show 2D model
  • LogP (experiment)2.0
  • LogP (predicted, AB/LogP v2.0)1.74
  • pkaN/A
  • LogD (pH=7, predicted)1.57
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-4.69
  • LogSw (predicted, AB/LogsW2.0)13.74
  • Sw (mg/ml) (predicted, ACD/Labs)0.01
  • No.of HBond Donors3
  • No.of HBond Acceptors10
  • No.of Rotatable Bonds4
  • TPSA118.21
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn ergot alkaloid used to treat migraines.
  • Absorption_value35.0
  • Absorption (description)Poorly absorbed after oral administration
  • Caco_2N/A
  • Bioavailability1.0
  • Protein binding93.0
  • Volume of distribution (VD)6 to 23 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmUndergoes extensive first-pass metabolism with considerable intersubject variation.
  • Half life2~4 h; a longer terminal elimination half-life of about 20 to 30 h has also been reported.
  • ExcretionAfter oral administration less than 5% of a dose is excreted in the urine unchanged in 24 h, compared to about 11% after intravenous administration. The major metabolite is the 8′-hydroxy derivative, which is active.
  • Urinary ExcretionN/A
  • Clerance15 ml/min/kg
  • ToxicitySide effects include abdominal pain, abnormal speech, coma, confusion, convulsions, hallucinations, increase and/or decrease in blood pressure, nausea, numbness, tingling, pain, and a bluish color of your fingersand toes, slowed breathing, vomiting
  • LD50 (rat)N/A
  • LD50 (mouse)N/A